antihypertensive
effect
spontaneously
heart
rate
produced
micrograms
kg
0.2
mg
alpha
partially
reversed
brain
membranes
M
influence
binding
nM
findings
indicate
central
adrenoceptor
stimulation
activation
receptors
receptor
site
observed
functional
antagonism
suggests
possible
role
control
induced
administration
bolus
year
old
resulted
apparent
associated
conditions
probably
represented
true
infusion
dose
response
study
chloride
administered
i.v
adult
males
rates
0.25
nerve
additional
patients
received
score
related
directly
group
groups
longer
acting
drug
effects
patient
non
neuromuscular
block
studies
high
protein
rats
HP
induce
female
containing
diet
mmol
normal
weeks
pretreated
generated
treated
versus
GFR
significant
changes
effective
renal
plasma
proximal
clearance
pretreatment
caused
fraction
Li
excretion
glomerulosclerosis
failed
progression
tended
increase
decrease
deterioration
results
reduced
corresponding
expression
glomeruli
tubular
fluid
TRUNCATED
fusidic
acid
immunosuppressive
properties
similar
T
cell
specific
new
treatments
pilot
treatment
chronic
active
therapy
resistant
included
orally
primarily
measured
individual
improved
reduction
cases
increases
elevated
levels
prior
pre
suggest
selected
conventional
level
inflammatory
bowel
evidence
ECG
abusing
controls
selective
D2
antagonist
antidepressant
initially
reported
developed
previous
reports
receiving
month
period
times
weekly
presented
clinical
symptoms
abnormalities
asymptomatic
retinal
origin
type
frequency
cochlear
withdrawal
complete
recovery
visual
function
partial
higher
doses
serum
data
complication
monitoring
adverse
history
3.0
mEq
L
tolerated
days
Hz
repetitive
revealed
rapid
exercise
suggesting
postsynaptic
blockade
strength
returned
single
fiber
increased
blocking
acetylcholine
antibody
markedly
Patients
sensitive
experimental
short
Based
indicating
important
metabolite
demonstrate
bladder
dysfunction
identical
application
placebo
onset
early
attack
second
induction
test
body
areas
inducing
direct
habitual
region
importance
CNS
derivative
observation
shows
cross
hepatotoxicity
long
term
basis
sustained
urinary
free
achieved
following
continuous
demonstrated
aldosterone
values
raised
concomitant
renin
leading
coagulation
rat
rise
model
lung
given
agent
changed
kidney
weight
considerably
lower
thrombin
II
secondary
mechanism
reduce
damage
randomized
comparison
major
procedures
anesthetic
protocol
reductions
mean
BP
mmHg
p
cardiac
decreased
efficacy
tissue
folate
concentrations
depletion
common
vehicle
protective
measure
maximal
toxic
animals
concentration
activity
dogs
day
sympathetic
release
minute
infusions
human
0.03
0.1
0.3
microgram
min
0.01
6.7
0.6
ng
immediately
greater
state
pg
ml
Multiple
cytotoxic
generally
risk
stage
multiple
drugs
consisted
D
schedule
moderate
died
massive
pulmonary
open
vascular
close
time
association
acute
likely
large
according
existing
develop
resistance
relatively
mild
initial
especially
previously
exposed
status
beta
combination
chemotherapy
matched
Scale
dysfunctions
morbidity
certain
sexual
scores
cause
nearly
fold
contrast
hemolytic
hemoglobin
AE
usually
red
cells
RBCs
formation
GSH
stability
shunt
compared
content
sensitivity
vivo
individuals
Given
United
States
oxidant
medications
caution
present
prevalence
identified
poor
suffering
III
severe
week
standard
initiated
addition
sample
recovered
discontinuation
months
later
past
oxidative
metabolism
genetic
population
brief
episodes
repeatedly
elderly
organic
mental
disorder
showed
tonic
h
differences
tolerance
strong
and/or
K
behaviour
signs
dopaminergic
experiments
real
degree
remained
striatum
process
known
injection
muscle
affected
right
examination
lesion
severely
head
good
subsequent
Recurrent
reversible
separate
component
volume
feedback
pacemaker
maximum
daily
predominantly
motor
gradual
improvement
followed
indicates
diagnosis
immediate
exposure
case
supports
endogenous
diminished
anti
agents
compensatory
subjective
oral
i.m
volunteers
0.5
number
subjects
sleep
earlier
sedation
significantly
saline
varied
size
X
double
including
follow
end
diastolic
unchanged
cows
parenteral
x
IU
pregnant
commonly
widespread
metastatic
low
peripheral
primary
malignant
disorders
peak
incidence
fourth
presentation
deficiency
mainly
frequent
system
structures
rare
factors
superior
overall
cardiovascular
clinically
laboratory
parameters
median
performance
design
impaired
recall
differ
tested
found
healthy
FANFT
fed
aspirin
suppressed
liver
index
experiment
different
mechanisms
ingestion
course
occurred
prescribing
particularly
F344
DES
preparations
populations
total
correlated
prolactin
PRL
culture
staining
density
alterations
unit
cycle
analysis
DNA
laser
1.3
ranged
positive
proportion
Increased
ovariectomized
stone
involvement
myocardial
inhibited
growth
contractions
characteristic
energy
suggested
charge
mM
adenosine
cultures
pathway
beating
Age
dependent
sulfate
age
movement
sensitivities
responsible
unusual
finding
rapidly
causes
underwent
regimen
biopsy
electron
interstitial
progressive
report
peroxidation
reducing
temporal
relationship
IV
PAN
7.5
hour
urine
samples
obtained
N
removed
reactive
peaked
injury
disturbance
releasing
action
secretory
controlled
night
intervals
underlying
procedure
intake
led
secretion
pulse
amplitude
altered
relative
vs
factor
nocturnal
intravenous
requiring
medical
elicited
include
inhibitors
blockers
resulting
developing
outcome
nicotinic
0.15
0.75
1.5
compounds
histopathological
bone
extensive
statistically
ultrasound
provides
animal
support
involving
PGE1
TMP
epidural
spinal
surgery
method
anaesthesia
intravenously
MAP
operative
starting
product
constant
g
Immunohistochemical
proteins
focal
lesions
monoclonal
antibodies
NF
molecular
class
pH
needle
pattern
immunohistochemical
medication
capacity
use
safe
therapeutic
produce
describes
transient
require
yr
gradually
lactam
antibiotic
bilirubin
Despite
Adverse
Group
Clinical
clinicians
quality
health
profiles
impairment
cognitive
measures
hepatic
anticholinergic
atypical
degrees
lowered
threshold
carefully
occurring
structure
mice
vitro
inhibition
platelet
tests
dependently
activities
activated
NSCLC
Recent
VNB
life
current
advanced
assessed
METHODS
Treatment
m(2
detected
RESULTS
value
survival
Health
Organization
Grade
remaining
years
vs.
prophylactic
colony
stimulating
combinations
vitamin
enhance
sufficient
gamma
matrix
inhibitor
artery
examined
d
restricted
prevents
young
ie
susceptibility
set
media
dramatically
chemical
observations
required
risks
antidepressants
optimal
paradigm
DSM
criteria
variables
sex
reuptake
mood
experienced
switching
attention
products
intractable
retention
noxious
stimuli
invasive
intensive
care
spontaneous
opioid
analgesic
Combined
antiretroviral
HAART
determine
mitochondrial
events
transgenic
TG
wild
echocardiography
markers
mRNA
ATPase
histologic
features
analyzed
transmission
microscopy
cohort
mass
cytoplasmic
cumulative
generation
i.e.
mutations
based
women
event
information
mutation
gene
odds
ratio
adjusted
2.5
4.1
0.7
2.1
1.9
nucleus
core
injected
microg
change
basal
locomotor
intra
attenuated
enhanced
agonist
enhancement
OBJECTIVE
investigate
main
characteristics
published
prolonged
percutaneous
coronary
remission
literature
objective
assessment
unclear
immune
mediated
counts
channel
ENaC
subunit
phase
completely
limiting
mRNAs
courses
Sprague
Dawley
amounts
alphaENaC
betaENaC
quantitative
regulation
conclusion
calcitonin
negative
correlation
delayed
provoked
P<0.01
intensity
P<0.001
consistent
correlates
vessel
routine
intracoronary
mm
segment
successfully
U
widely
i.c.v
behavioral
little
injections
metabolic
endocrine
responses
Administration
mouse
board
white
plus
maze
tail
food
water
locomotion
apomorphine
climbing
behavior
demonstrates
induces
like
knowledge
pharmacological
modulation
states
skin
surrounding
nociceptive
fMRI
mechanical
bilateral
cortex
independently
brainstem
stimulus
baseline
signal
antinociceptive
antihyperalgesic
MDMA
polydrug
users
impairments
emotional
processes
recent
memory
deficits
aimed
completed
general
task
Inhibition
scale
apheresis
donor
minutes
noted
facial
reaction
systemic
retrospective
careful
screening
prevent
reactions
measurement
vigilance
SRL
potent
recently
retrospectively
conversion
men
transplantation
3.2
dL
range
performed
pathological
0.8
dialysis
3.5
de
novo
pathology
muscarinic
neuronal
investigated
adrenergic
antagonists
atropine
types
frequencies
evoked
substantial
occur
inhibitory
physical
abilities
associations
RDs
aged
hospital
deviation
half
admission
ability
MMSE
points
records
confounding
residual
concomitantly
taken
Long
shorter
potentially
intoxication
sensory
loss
conduction
movements
improve
recurrent
antigen
assay
step
HIT
count
OD
0.4
isolated
difference
females
SETTING
MAIN
OUTCOME
Chinese
NIN
unknown
eye
nuclei
gastric
hemorrhagic
mucosal
lacking
diffusion
LPO
microvascular
permeability
evaluated
oil
determined
autophagic
novel
randomly
divided
morphology
membrane
potential
vacuoles
frequently
work
occurs
older
neural
face
learning
shown
hippocampal
cortical
regions
predominant
cannabis
hyperactivity
anterior
medial
gyrus
elevation
argatroban
suspected
Direct
provide
alternative
transfusion
postoperatively
ECT
mL
surgical
remain
magnitude
profile
prognosis
ATT
South
prospectively
prognostic
1.2
prescribed
duration
seven
enzymes
mortality
multivariate
seconds
grade
pediatric
institution
problem
electrophysiological
late
neurocognitive
defects
collected
neurological
children
line
detection
review
safety
better
chemotherapeutic
established
plays
critical
recordings
neurons
blocked
rating
regular
methyl
dopa
CPAP
QS
QT
H2O
decreasing
marked
reflex
oxidase
restored
vasoconstriction
remains
medium
vessels
intact
cerebral
perfusion
SPECT
neuroleptic
described
Repeated
scans
tablets
titrated
stable
average
3.8
hours
2.4
gastrointestinal
systems
medullary
structural
stages
irreversible
defect
volumes
sectional
osmolality
dosing
affect
tissues
antitumor
delay
physiological
morphological
C
1.6
ratios
estimated
combined
blocker
neck
septal
akathisia
implications
appeared
authors
tricyclic
despite
intramuscular
studied
intracerebral
increasing
adults
Drug
Systolic
minimal
SBP
subjected
SNP
capillary
pressures
Analysis
respiratory
0.02
intracranial
condition
methods
subarachnoid
technique
min-1
2.2
protection
pregnancy
infant
twin
fatal
fulminant
discontinued
extent
intermittent
resolution
reviewed
sites
anesthesia
competitive
torr
post
mixed
viral
disturbances
determination
preventing
hematologic
prospective
CD4
dl
assigned
beneficial
neurologic
lasting
highly
fully
analogue
treat
ampicillin
SUMMARY
manifestation
amoxicillin
antibiotics
RAST
challenge
BPO
PG
having
employed
involved
anionic
ultrastructural
computerized
image
showing
abolished
p<0.001
0.9
surface
albumin
MTX
evaluation
0.0001
kidneys
series
preliminary
MFL
benefit
m2
anthracycline
radiotherapy
hormone
7.6
relapse
needed
consciousness
absorption
interaction
specimens
biopsies
episode
rejection
form
synthesis
PG-9
NGF
prevented
M1
highest
motility
useful
diagnosed
minor
manifestations
room
small
OC
repeat
patterns
pills
analyses
comparisons
consecutive
repeated
development
latency
serotonergic
paper
pharmacologic
limited
simultaneously
native
PTCR
predictive
sigma
Swiss
LR132
GABA(A
NMDA
lethality
provided
putative
characterized
Pharmacokinetic
dog
e.g.
circulation
target
regimens
closely
causing
accidental
intrathecal
investigations
degeneration
macrophages
trial
Study
participants
solution
statistical
cholinergic
convulsant
lines
alcohol
severity
WSP
WSR
carbachol
hippocampus
reverse
twice
extracellular
intraperitoneal
P<0.05
prenatal
acetate
EE
Research
reference
androgen
D1
CAB
3.75
intramuscularly
Hb
recorded
abnormal
upper
easily
subcutaneous
echocardiographic
available
lemon
need
OP
DFP
anticonvulsant
hydrogen
typical
Differential
alpha2
autonomic
hemodynamic
variability
sham
operated
Ovx
wk
replacement
R
wave
TCR
extract
antioxidant
protected
raloxifene
outcomes
multicenter
gallbladder
3.3
RR
excess
1.1
2.7
serial
abdominal
resolved
GNC92H2
albino
behaviors
fibrinolysis
TAFI
tPA
hydrochloride
Daucus
carota
functions
DCE
models
testing
acetylcholinesterase
lowering
possibly
bupivacaine
leg
space
area
catheter
continued
self
aorta
adjustment
immunosuppressant
actions
kinase
exhibited
appears
calcineurin
appropriate
endoplasmic
reticulum
cyclic
nucleotide
channels
tone
independent
targeted
newborns
neonates
hearing
smokers
utero
impact
preterm
labor
microglial
urgent
sudden
recognized
valproate
added
VPA
EEG
generalized
slowing
Dbh
signaling
arm
exploration
J
3.4
Physicians
refractory
evaluable
12.5
2.6
management
instillation
ocular
pegylated
interferon
examinations
indicated
rarely
SSR103800
antipsychotic
result
particular
amphetamine
MK-801
transporter
S(c)O(2
l
symptom
biochemical
future
strategies
taking
stopped
prematurely
microscopic
topical
1/2
percentage
environment
stimulant
pronounced
located
local
catheterization
blinded
IGF
chest
anesthetized
antiviral
electrocardiographic
portal
glucocorticoid
alfentanil
ICP
entire
ST
documented
near
recommended
decreases
morning
NTE
Mipafox
Brain
cord
hr
dosed
predict
synthetic
histological
intracarotid
unilateral
intrarenal
kg-1
4.8
defined
approximately
cytochrome
P450
organs
slight
bicarbonate
intracorporeal
normalized
stones
PD
disabling
cerebellar
BBB
layer
endothelial
distinct
Golgi
haemolytic
angiography
escape
workers
hepatocellular
hepatocytes
deficit
point
uneventful
slow
accumulation
postoperative
complex
appetite
suppressants
substance
erythrocytes
TAM
erythrocyte
microM
inhibits
K)-ATPase
deficient
transport
synthase
arginine
ester
profound
affinity
bromocriptine
developmental
production
brush
punctate
differential
concurrent
organ
monitored
apoptotic
GSPE
Kg
DOX
ALT
fragmentation
sections
effectively
twitching
intestinal
potentiation
waves
GABA
GVG
preclinical
treating
sub
collagenase
protect
cost
sequelae
evaluations
CT
illustrates
mucosa
applied
dentate
untreated
recording
strains
beta4
subunits
alpha3
selectively
middle
auditory
diagnostic
interactions
Tenon
Hospital
comprised
B
significance
Cardiac
SCr
postdose
micromol
0.07
compound
neuroprotective
HBV
infected
exploratory
HBsAg
Srl
METH
CX3CR1
MPTP
green
fluorescent
depleted
seen
striatal
brachial
regurgitation
neurophysiological
monitor
BAEP
LDL
SGK1
sgk1(-/-
sgk1(+/+
reached
trimoxazole
subset
a.m.
abstinence
fixed
podocyte
foot
protease
recommend
HT
assess
occupancy
unique
failure
aminotransferase
elevations
practitioners
distribution
variants
BCHE
5.3
emergency
fracture
experience
TEE
semi
MZ
MR
consequences
withdrawn
ratings
stretch
painful
understood
rTMS
cyanamide
consumption
D3
alpha1
TRI
poorly
threatening
rhesus
monkeys
WR242511
MHb
CN
essential
A1
pen
distance
dependency
National
research
antiarrhythmic
polymorphous
premature
foci
emergent
10(-3
3.6
interpeduncular
dP
dtejc
dosage
squamous
approach
receive
ambulatory
fetuses
aortic
reactivation
mutants
sP120
replication
LAM
HBeAg
eNOS
segments
uptake
images
0.50
strain
MPEP
mGluR5
label
DOPA
LID
uraemic
M.S.
trough
hepatocyte
TJs
ZO-1
BDL
adjunctive
IL-3
Na]o
Ca]o
atrial
BF
LNa
intraperitoneally
weighted
Initial
ADC
subsequently
regression
cTnI
cTnT
CK
FS
Japan
probable
aprotinin
sugar
access
deprivation
sucrose
chow
131I
radical
trials
investigating
allocated
mtDNA
RAMH
THP
amifostine
nuclear
DFU
larger
BMC
OLTX
DBP
gall
immunohistochemistry
B6
LY274614
MMP-2
MMP-9
NaCl
CaCl(2)-treated
PAC
mToR
LH
CIS
cholesteryl
E2
MRP2
TR(-
Pgp
inbred
CSS
CCO
E18.5
BALB
MAHA
amantadine
bupropion
indocyanine
angiogenesis
haptoglobin
NFkappaB
retrieval
/-)-PG-9
guinea
piriform
PDTC
gum
LIDs
ng./ml
FK
CGI
SF
P=
Rg1
orofacial
GM
GLEPP1
heart rate
micrograms/
/kg
mg/
kg.
alpha-
rate.
nM)
-adrenoceptor
-mg
-year
year-
-old
dose-
-response
study.
i.v.
dose.
infusion.
drug,
blood-
non-
rats.
-containing
mmol/
kg)
diet,
weeks.
-treated
groups,
plasma flow
Li-
-pretreated
-induced
reduced,
T-
-cell
-resistant
patients.
pre-
-treatment
-receptor
receptor antagonist
properties.
-month
-type
high-
-frequency
levels.
adverse effects
mEq/
/L
L,
effects,
group.
-inducing
recovery.
long-
-term
levels,
term treatment
-related
rat.
man.
ACE)
rat model
model.
-blocking
blocking agent
agent.
study,
group)
procedures.
drug-
(p
cardiac output
findings.
antiepileptic drug
therapy.
studies.
high doses
doses,
adverse effect
kg/
/day
day,
-minute
microgram/
/min
0.01)
min)
ng/
(0.1
min.
plasma concentrations
pg/
/ml
(n
drugs.
-D
treatment,
drug.
beta-
-matched
controls.
-associated
Heinz body
day)
-exposed
drug therapy
function.
ml)
drugs,
control.
brief episodes
activation.
treatment.
(0.2
-week
volume,
mg,
renal function
anti-
-inflammatory
i.m.
administration.
effects.
(placebo
end-
period.
double-
subjects.
cell proliferation
induced increase
patients,
mg)
DES-
single-
weight,
analysis,
exposure.
exposure,
PRL-
-positive
animals.
system.
cells.
significantly decreased
-dependent
age,
weeks,
puromycin aminonucleoside
(N
lipid peroxidation
-releasing
effect.
placebo-
-controlled
conditions,
procedure.
angiotensin-
-blockers
blockers.
0.75%
treated chicks
statistically significant
animal model
surgery,
patients)
group,
ml/100 g
g/
NF-
use,
nervous system
sedation,
changes,
tests,
nonsmall cell
cell lung
BACKGROUND:
METHODS:
/m(2
m(2)
days.
RESULTS:
overall response
response rate
partial response
response.
performance status
gamma-
matrix Gla
Gla protein
smooth muscle
-day
day-
ad libitum
/d
-inhibited
ie,
High doses
analysis showed
risk factors
DSM-
-IV
sex,
electroconvulsive therapy
patient,
contrast,
-existing
unit,
mice.
wild-
-generation
(i.e.
i.e.,
second-
-based
case-
nucleus accumbens
receptors)
0.1-
activity.
significantly increased
intra-
accumbens shell
-dependently
OBJECTIVE:
literature.
unclear.
function tests
-limiting
Sprague-
-Dawley
alphaENaC,
-time
injection.
mRNA expression
conclusion,
gene-
(mean
increased significantly
P<0.01)
showed significant
toxic effects
right coronary
coronary artery
-II
U-
i.c.v.
/mouse
test,
test.
body temperature
apomorphine-
level.
-like
cortex,
-specific
processes.
working memory
-free
controls,
use.
renal transplant
transplant recipients
immunosuppressive agent
therapy,
transplantation.
follow-
months.
/dL
remained unchanged
range.
urinary protein
renal transplantation
investigated.
electrical field
field stimulation
-evoked
-mediated
years)
users.
variables.
(range
Long-
high dose
-dose
: Patients
isolated-
-HIT
-fold
DESIGN:
-diffusion
diffusion,
evaluated.
ml/
normal saline
low-
acid.
years.
addition,
cortex.
cardiac transplant
range,
microg/
/mL
mL)
agents,
outcome.
ATT-
outcome,
dL)
adverse events
events.
period,
-line
symptoms.
QS/
/QT
pressure,
rate,
QT.
L-
-dopa
dogs.
-beta
inhibitor,
: clinical
-pressure
data suggest
short-
-acting
urinary concentrating
concentrating ability
analgesic treatment
damage.
day.
cross-
-sectional
daily dose
adrenergic receptors
receptors.
induced akathisia
-tolerated
Drug-
year.
(SBP
SBP)
groups.
mm Hg
report.
man,
chemotherapy.
pregnancy,
abnormalities.
reported.
infusion,
min,
post-
prospective,
CD4+
/dl
given.
High-
case report
SUMMARY:
history,
-L
function,
studies,
heparan sulphate
anionic sites
basement membrane
rats,
enzymes,
lamina rara
rara externa
(p<0.001
administration,
treatment-
regimen.
/m2
m2,
cumulative dose
occurred.
renal allografts
renal allograft
mild-
growth factor
avoidance test
-selective
activity,
chronically treated
injury,
GABA(A)
NMDA receptors
(e.g.
days,
controlled trial
trial.
months,
 ve
mice,
withdrawal.
P<0.05)
(P<0.05
/EE
age-
symptoms,
-CAB
dl,
women.
alpha2-
-adrenergic
sham-
-operated
-wave
-R
marker enzymes
postmenopausal women
years,
(RR
passive avoidance
imaging.
later,
hours.
self-
immunosuppressive therapy
white matter
open field
microglial activation
FINDINGS:
II trial
regimens.
protective effect
antipsychotic-
like profile
N-
-methyl
methyl-
D-
NMDA)
receptor.
hyperactivity,
antagonist,
system,
-effect
S(c)O(2)
treatment groups
IGF-
open-
observed.
-h
surgery.
ST-
-T
dose,
weeks)
days)
adverse reactions
(pH
gallbladder contractility
(PD
PD)
endothelial cells
spinal anaesthesia
anaesthesia.
appetite suppressants
disorders.
TAM-
nitric oxide
-arginine
(L
-deficient
increased,
bromocriptine-
significantly reduced
variables,
brush-
punctate-
controlled,
organ transplantation
transplantation,
week later
renal artery
groups:
/Kg
-chronic
low dose
induced increases
sub-
-unit
later.
mRNA levels
induced acute
-drug
drug interactions
-Tenon
results.
micromol/
L)
SCr increases
increases >
-negative
HBV)
-infected
resistant strains
tail-
time-
-inhibitor
(median
half-
-trimoxazole
-release
middle-
-aged
older adults
placebo,
sleep time
time,
twice daily
foot process
agent,
-HT
saline,
doses.
hepatic failure
aminotransferase levels
IU/
/l
l,
semi-
p<0.001)
Recently,
minutes.
alpha1-
(given
understood.
laser pointer
life-
-threatening
significant.
repair synthesis
10(-3)
dP/
/dtejc
cost-
U/
inhibitors.
Phase II
amphetamine-
immune escape
strains.
segments.
dose)
renal ACE
ACE activity
-DOPA
VPA-
-uraemic
haemolytic-
hepatic dysfunction
dysfunction.
bone marrow
-IL-3
[Na]o
-depleted
-loaded
inferior colliculus
-weighted
LV diameters
-systolic
FS containing
injection,
-pen
131I-
natriuretic peptide
-stimulating
minutes,
selective COX-2
mononuclear cells
gall stones
secretory granules
ribosomal RNA
-alpha
treatment period
intrarenal angiotensinogen
HS diet
diet.
antiepileptic drugs
mouse strains
initial MR
BALB/
-devoid
devoid diet
indocyanine green
+/-)-PG-9
ng./ml.
determination.
activity-
CGI-
-SF
(P=
-second
second injection
-test
test conditions
micrograms/kg
mg/kg
/kg.
-year-
year-old
dose-response
blood-brain
-brain barrier
/kg)
glomerular filtration rate
T-cell
pre-treatment
/L,
long-term
kg),
drug-induced
/kg/
kg/day
/day,
microgram/kg
kg/min
0.001),
), respectively
/min)
/min.
pg/ml
(n =
high-risk
-year old
mg/day
/day)
ng/ml
/ml)
anti-inflammatory
-treated patients
puromycin aminonucleoside-
aminonucleoside-induced
beta-blockers
%, respectively
dose-dependent
central nervous system
. BACKGROUND:
. METHODS:
mg/m(2
/m(2)
. RESULTS:
% confidence interval
. CONCLUSIONS:
-day-
g/d
risk factors.
DSM-IV
. CONCLUSION:
wild-type
-HT1B receptor
dose-dependently
U-II
i.c.v.)
apomorphine-induced
n = 8)
0.001).
mg/dL
. OBJECTIVE:
-term use
isolated-HIT
-treated group
. Furthermore,
(range,
/mL)
%) patients
) patients.
/dL)
high-dose
QS/QT
blood pressure,
/QT.
L-dopa
. Finally,
. METHOD:
Drug-induced
(SBP)
g/dl
-L-
short-acting
control rats,
mg/m2
/m2,
mild-type
Wistar rats.
randomized, double
) mice.
(P<0.05)
months post-
post-CAB
/dl,
0.01).
microg/kg
sham-operated
mg kg(-1)
multicenter, randomized
%) developed
short-term
controls (n
beta-adrenergic
antipsychotic-like
N-methyl
-methyl-
methyl-D
-D-
frontal lobe oxygenation
-induced locomotor
-induced hyperactivity
kg).
liver function tests
low-dose
vanishing bile duct
L-arginine
(L-
. PURPOSE:
sub-Tenon
-risk patients
estimated glomerular filtration
micromol/L
/L)
-infected patients
(PD)
sgk1(-/-) mice
sgk1(+/+) mice
middle-aged
ml/min
IU/l
/l,
i.p.,
non-selective
(r =
) mol/
dP/dtejc
U/L
amphetamine-induced
L-DOPA
D-pen
(AOR =
-lipoic acid
alpha-lipoic
L);
L-alpha
-alpha-
PRL-R
BALB/C
/C mice
(+/-)-PG-9
activity-increasing
-increasing effects
-year-old
year-old man
blood-brain barrier
mg/kg)
/kg),
mean arterial blood pressure
/kg/day
kg/day,
microgram/kg/
/kg/min
ng/ml)
year-old woman
-dependent manner.
mg/m(2)
Eastern Cooperative Oncology Group
). CONCLUSIONS:
-day-old
). CONCLUSION:
case-control study
percent confidence interval,
Sprague-Dawley rats
10,000 ng/mouse
, apomorphine-induced
. Long-term
mg/dL)
, placebo-controlled
(mean +/-
year-old boy
, respectively).
-type chronic FK506
, P<0.05),
i.p.).
mg/kg/
N-methyl-
-methyl-D
methyl-D-
/kg).
(0.5 mg/
virus (HBV)
IU/l,
mg. l(-1)
, p.o.,
% (P =
U/L)
/L);
L-alpha-
left ventricular posterior wall
-year-old man
converting enzyme (ACE)
/kg/day,
microgram/kg/min
/kg s.c.)
male Sprague-Dawley rats
/kg i.v.)
-year-old male
mg/kg/day
N-methyl-D
-methyl-D-
/kg p.o.)
U/L);
(P < 0.05).
N-methyl-D-
mg/kg, i.p.)
(2.0 mg/kg BW)
N-methyl-D-aspartate (NMDA)
